Veteran private markets investor and operating executive with a track record of sourcing and scaling middle-market businesses across technology and industrial sectors. Jeffrey McGrath brings experience in buyouts, growth equity and operational transformation, with a focus on driving EBITDA expansion, margin enhancement and strategic M&A. Known to take active board and management roles, he prioritizes value creation through commercial growth, cost optimization and talent development. Relevant to limited partners and acquirers assessing sponsor-driven operational upside.
Veteran private markets investor and operating executive with a track record of sourcing and scaling middle-market businesses across technology and industrial sectors. Jeffrey McGrath brings experience in buyouts, growth equity and operational transformation, with a focus on driving EBITDA expansion, margin enhancement and strategic M&A. Known to take active board and management roles, he prioritizes value creation through commercial growth, cost optimization and talent development. Relevant to limited partners and acquirers assessing sponsor-driven operational upside.
Focuses on hands‑on, operationally driven private markets investing in middle‑market technology and industrial companies, blending buyout and growth equity tactics to unlock EBITDA expansion. Prefers control or influential minority positions where active board engagement, commercial scale‑up, cost optimization and targeted M&A can accelerate margin improvement. Capital allocation emphasizes measurable operational KPIs, disciplined leverage, staged value‑creation milestones and a 3–7 year horizon to crystallize gains via strategic exits or sales to strategic acquirers.
Focuses on hands‑on, operationally driven private markets investing in middle‑market technology and industrial companies, blending buyout and growth equity tactics to unlock EBITDA expansion. Prefers control or influential minority positions where active board engagement, commercial scale‑up, cost optimization and targeted M&A can accelerate margin improvement. Capital allocation emphasizes measurable operational KPIs, disciplined leverage, staged value‑creation milestones and a 3–7 year horizon to crystallize gains via strategic exits or sales to strategic acquirers.
| Trades 1640 | Longs Won 1124/1640 68% | Profit Factor 7.96 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $318,728.8 |
| Average Win $76,107.75 | Best Trade (Aug 14) $9.46M | Sharpe Ratio -295.82 |
| Average Loss -$20,828.82 | Worst Trade (Sep 30) -$728,555.57 | Z-Score 14.22 (100%) |
| Commissions $0 | Avg. Trade Length 1y 4m 4w | Expectancy $45,608.19 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 9,615 | 8,654 | 7,692 | 6,731 | 5,769 | 4,808 | 3,846 | 2,885 | 1,923 | 962 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
A Agilent Technologies Inc. | 50 | $6,951.5 | $7,412 | - | $460.5 | 6.62% | 0.0 |
AAPL Apple Inc. | 39,492 | $7.6M | $12.06M | - | $4.45M | 58.55% | +0.996% |
ABBV AbbVie Inc. | 668 | $103,520 | $166,171.67 | - | $62,651.67 | 60.52% | 0.0 |
ABT Abbott Laboratories | 3,656 | $402,415.95 | $405,486.96 | - | $3,071.01 | 0.76% | 0.0 |
ACIW ACI Worldwide, Inc. | 6,335 | $266,434.05 | $334,171.25 | - | $67,737.2 | 25.42% | 0.0 |
ADI Analog Devices, Inc. | 146 | $28,990 | $56,126.78 | - | $27,136.78 | 93.61% | 0.0 |
ADUS Addus HomeCare Corporation | 2,820 | $272,367.88 | $332,929.2 | - | $60,561.32 | 22.24% | 0.0 |
AFL Aflac Inc. | 118 | $9,735 | $14,246.14 | - | $4,511.14 | 46.34% | 0.0 |
AIG American International Group Inc. | 17,971 | $1.34M | $1.37M | - | $27,241.23 | 2.03% | 0.0 |
AIZ Assurant Inc. | 60 | $10,109 | $16,867.2 | - | $6,758.2 | 66.85% | 0.0 |
AJG Arthur J. Gallagher & Co. | 34 | $7,646 | $8,685.64 | - | $1,039.64 | 13.6% | 0.0 |
ALB Albemarle Corporation | 1,960 | $260,180.56 | $255,740.8 | - | -$4,439.76 | -1.71% | +1.667% |
ALL Allstate Corporation | 78 | $10,918 | $19,955.52 | - | $9,037.52 | 82.78% | 0.0 |
ALNY Alnylam Pharmaceuticals Inc | 16 | $3,063 | $3,583.2 | - | $520.2 | 16.98% | 0.0 |
AMAT Applied Materials, Inc. | 998 | $161,746 | $533,470.92 | - | $371,724.92 | 229.82% | -2.483% |
AMD Advanced Micro Devices, Inc. | 104 | $15,331 | $50,224.72 | - | $34,893.72 | 227.6% | 0.0 |
AMG Affiliated Managers Group Inc. | 1,640 | $285,918.7 | $594,336 | - | $308,417.3 | 107.87% | 0.0 |
AMGN Amgen Inc. | 8,983 | $2.59M | $3.74M | - | $1.14M | 44.14% | 0.0 |
AMH American Homes 4 Rent | 5,095 | $180,243.47 | $172,363.85 | - | -$7,879.62 | -4.37% | 0.0 |
AMP Ameriprise Financial, Inc. | 1,050 | $398,821.5 | $593,323.5 | - | $194,502 | 48.77% | 0.0 |